# Hangzhou Adamerck Pharmlabs

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hangzhou-adamerck-pharmlabs

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.adamerck.net
- Total disclosed funding: $46M
- Latest round: Series B (Aug 25, 2021)
- Investors on record: 5

## About

Based in Zhejiang, China and founded in 2000, Hangzhou Adamerck Pharmlabs Inc. is a pharmaceutical enterprise, being dedicated to the research and development of innovative drug. The company was founded by Youmao Qi, a Doctor returned from overseas.  Up to now, the company has declared more than 25 domestic patents for invention and 3 international patents for invention, developed 5 new drugs in State Category 1, and accomplished the registration of more than 100 projects to CFDA. Adamerck has established research and development center and academician workstation including the screening platform for chemical drugs, natural drugs and medicinal preparations. The company also has a drug manufacturing base which is able to process APIs, solid preparations and injections.

Muscle relaxant antagonist Aom0498 is the company first independent target muscle relaxant, which has entered the clinical trial stage. It is helpful for patients to restore spontaneous breathing after operation, it can also used to reduce side effects and emergency rescue. The company also has other new drug projects such as Anti-thrombotic Aom0315, Intravenous anesthetic Aom0765 and Weight-Loss Drug Aom1110. The company's research involves drugs for anesthesia, cardiovascular system, weight loss, diabetes, hypnosis and tumor.

## Funding rounds

- Series B, Aug 25, 2021, $46M — Homsun Capital, Juren Capital, Hangzhou Miyin Investment Management, Shanghai Chunshan Pujiang Investment Management, Hangzhou Yuanhenglizhen Equity Investment Management

## Investors

- Homsun Capital (https://capitalatlas.ai/funds/homsun-capital) — Series B
- Juren Capital (https://capitalatlas.ai/funds/juren-capital) — Series B
- Hangzhou Miyin Investment Management — Series B
- Shanghai Chunshan Pujiang Investment Management — Series B
- Hangzhou Yuanhenglizhen Equity Investment Management — Series B